{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Maximum tolerated dose of bendamustine in combination with fixed doses of ixazomib (MLN9708) and dexamethasone will be determined from the incidence of dose limiting toxicities at each dosage.","groups":[{"description":"MLN9708: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.\n\nDexamethasone: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.\n\nBendamustine:70 mg/m\\^2, 80 mg/m\\^2, or 90 mg/m\\^2 on days 1 and 2","id":"OG000","title":"MLN9708, Bendamustine and Dexamethasone"}],"paramType":"NUMBER","populationDescription":"All participants received at least ne dose of Bendamustine at either 70 mg/m\\^2, 80 mg\\^2 or 90 mg/m\\^2.","reportingStatus":"POSTED","timeFrame":"Six months for each dosing cohort","title":"Maximum Tolerated Dose of Bendamustine","type":"PRIMARY","unitOfMeasure":"mg/m^2"}